ArticleCell division2024
ZEB2 reduction contributes to pre-eclampsia via Wnt/β-Catenin pathway.
Article in Cell division, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPre-eclampsia (PE) is a pregnancy specific disease characterized by hypertension and proteinuria. The aim of this study was to investigate the effects of Zinc finger E-box binding homologous box 2 (ZEB2) on PE mice and on placental trophoblast cells, as well as to elucidate its role in Wnt/β-Catenin pathway.
methodsThe PE mice models were established through L-NAME administration. RT-qPCR and western blot assay were used to detect the expression of ZEB2 in human serum, placental tissues, HTR8/Sveno cells, and mice models. Edu assay, flow cytometry, and Transwell analysis were applied for determining HTR8/Sveno cells proliferation, apoptosis, migration, and invasion ability, respectively. The expression levels of related proteins in the Wnt/β-Catenin pathway were detected by western blot analysis. The systolic blood pressure (SBP) of mice was analyzed by the noninvasive tail cuff method. Proteinuria was detected using CBB kits and TUNEL method was used to measure apoptosis of placental tissue cells in PE mice.
resultsThe significant increase SBP and urinary protein in L-NAME treated mice indicated the successful construction of the PE mice model. We found that ZEB2 was down-regulated in the serum and placental tissues of PE patients. Further in vitro experiments showed that ZEB2-plasmid enhanced cell proliferation, migration, and invasion, as well as reduced cell apoptosis, compared with the control-plasmid group. In addition, up-regulation of ZEB2 promoted the protein level of Bcl-2 in HTR-8/SVneo cells and inhibited Bax expression. We also found that ZEB2-plasmid activated Wnt/β-Catenin signaling pathway, as confirmed by enhanced Wnt3a, β-Catenin, p-GSK3β, C-Myc, and Cyclin D1 expression. Importantly, the Wnt/β-Catenin signaling inhibitor (XAV939) partially reversed the effects of ZEB2-plasmid on HTR-8/SVneo cells. We also observed similar findings in in vivo mice models as in vitro cell experiments.
conclusionZEB2 was involved in the pathological and physiological processes of PE through Wnt/β-Catenin pathway, which may provide a useful perspective for exploring new therapies for PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.